Answer questions and earn CME/CNE Advances in genomics and molecular biology have
identified aberrant proteins in cancer cells that are attractive targets for cancer therapy …

Cardiovascular toxicity remains a major cause of concern during preclinical and clinical
development as well as contributing to post-approval withdrawal of medicines. This issue is …

Background Several randomised trials have confirmed the benefit of adjuvant trastuzumab
for patients with HER2-positive early breast cancer. However, concern has been expressed …

Background Central nervous system (CNS) disease as the site of first relapse after exposure
to adjuvant trastuzumab has been reported. We carried out comprehensive meta-analysis to …

Because metastatic breast cancer (MBC) is incurable in most cases, the goals of treatment
are improvement in quality of life, management of symptoms, and prolonged survival. The …

It has long been recognized in breast cancer that the effect of hormone receptor (HR) status
on recurrence rates varies over time and with the site of recurrence. However, there is …

Brain metastases (BM) are the most common intracranial tumors and their incidence is
increasing. Untreated brain metastases are associated with a poor prognosis and a poor …

Nohria β-Blockers—Protection Against Cardiotoxicity? 359 of symptomatic HF observed in
this study reflect less rigorous monitoring of LV function during trastuzumab therapy in a real …

Purpose A challenge in management of breast cancer is the development of brain
metastases (BM). Because of improvements in systemic therapy with longer survival of …

Opinion statement Molecular subtyping of tumors and treatment with specifically targeted
therapy is a rapidly developing trend in oncology. Genetic and protein biomarkers impact …